ACET
Price
$8.18
Change
-$0.05 (-0.61%)
Updated
Jun 23, 04:56 PM (EDT)
Capitalization
76.19M
44 days until earnings call
Intraday BUY SELL Signals
ZSTK
Price
$4.04
Change
-$0.00 (-0.00%)
Updated
Jun 23, 03:55 PM (EDT)
Capitalization
9.82M
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACET vs ZSTK

ACET vs ZSTK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ACET vs. ZSTK commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and ZSTK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (ACET: $8.23 vs. ZSTK: $4.04)
Brand notoriety: ACET and ZSTK are both not notable
ACET represents the Biotechnology, while ZSTK is part of the Investment Managers industry
Current volume relative to the 65-day Moving Average: ACET: 65% vs. ZSTK: 28%
Market capitalization -- ACET: $76.94M vs. ZSTK: $9.82M
ACET [@Biotechnology] is valued at $76.94M. ZSTK’s [@Investment Managers] market capitalization is $9.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The market cap for tickers in the [@Investment Managers] industry ranges from $163.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2B. The average market capitalization across the [@Investment Managers] industry is $9.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 1 FA rating(s) are green whileZSTK’s FA Score has 0 green FA rating(s).

  • ACET’s FA Score: 1 green, 4 red.
  • ZSTK’s FA Score: 0 green, 5 red.
According to our system of comparison, ACET is a better buy in the long-term than ZSTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 5 TA indicator(s) are bullish while ZSTK’s TA Score has 3 bullish TA indicator(s).

  • ACET’s TA Score: 5 bullish, 5 bearish.
  • ZSTK’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ACET is a better buy in the short-term than ZSTK.

Price Growth

ACET (@Biotechnology) experienced а +1.48% price change this week, while ZSTK (@Investment Managers) price change was -17.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

The average weekly price growth across all stocks in the @Investment Managers industry was -2.28%. For the same industry, the average monthly price growth was -2.46%, and the average quarterly price growth was -8.13%.

Reported Earning Dates

ACET is expected to report earnings on Aug 06, 2026.

ZSTK is expected to report earnings on Aug 17, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Investment Managers (-2.28% weekly)

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACET($76.2M) has a higher market cap than ZSTK($9.82M). ACET YTD gains are higher at: -2.257 vs. ZSTK (-35.463). ACET has higher annual earnings (EBITDA): -102.73M vs. ZSTK (-151.12M). ACET has more cash in the bank: 138M vs. ZSTK (1.98M). ZSTK has less debt than ACET: ZSTK (3.55M) vs ACET (13.9M). ZSTK has higher revenues than ACET: ZSTK (36.1M) vs ACET (0).
ACETZSTKACET / ZSTK
Capitalization76.2M9.82M776%
EBITDA-102.73M-151.12M68%
Gain YTD-2.257-35.4636%
P/E RatioN/AN/A-
Revenue036.1M-
Total Cash138M1.98M6,977%
Total Debt13.9M3.55M392%
FUNDAMENTALS RATINGS
ACET: Fundamental Ratings
ACET
OUTLOOK RATING
1..100
42
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
25
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACETZSTK
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
82%
Bullish Trend 20 days ago
86%
Declines
ODDS (%)
Bearish Trend 16 days ago
88%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ACET
Daily Signal:
Gain/Loss:
ZSTK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRBP8.340.08
+0.97%
Corbus Pharmaceuticals Holdings
ANRO22.930.19
+0.84%
Alto Neuroscience
HAL35.170.24
+0.69%
Halliburton Company
KAPA0.43N/A
+0.23%
Kairos Pharma Ltd.
CAKE76.92-0.27
-0.35%
Cheesecake Factory

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with KURA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
+1.60%
KURA - ACET
45%
Loosely correlated
+4.33%
RXRX - ACET
43%
Loosely correlated
-2.01%
VIR - ACET
42%
Loosely correlated
+4.48%
OGI - ACET
41%
Loosely correlated
+0.34%
FATE - ACET
41%
Loosely correlated
+2.39%
More

ZSTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZSTK has been loosely correlated with SNDL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ZSTK jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZSTK
1D Price
Change %
ZSTK100%
N/A
SNDL - ZSTK
37%
Loosely correlated
-1.06%
ACET - ZSTK
34%
Loosely correlated
+1.60%
SXTC - ZSTK
26%
Poorly correlated
+7.17%
IMCC - ZSTK
26%
Poorly correlated
-4.75%
RMTI - ZSTK
24%
Poorly correlated
+4.56%
More